Trial Profile
A Phase I Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Mar 2019
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine H7N9 (Primary) ; Influenza virus vaccine live (Primary)
- Indications Influenza A virus H7N3 subtype; Influenza A virus H7N9 subtype
- Focus Pharmacodynamics
- 22 Mar 2019 Status changed from recruiting to completed.
- 17 Jul 2018 New trial record